Price$14.95+0.27 (+1.84%)
01:30 PM07:45 PM
News · 26 weeks38-91%
2025-12-142026-06-07
Mix2090d
- Insider8(40%)
- SEC Filings6(30%)
- Other4(20%)
- Earnings2(10%)
Latest news
25 items- PRNew REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with HypertriglyceridemiaDUBLIN and BRIDGEWATER, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) (Amarin), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today announced new data from a post hoc analysis of the REDUCE-IT® trial presented at the European Atherosclerosis Society (EAS) Congress 2026 in Athens, Greece. The analysis, conducted in the REDUCE-IT placebo arm, evaluated risk-weighted apolipoprotein B (RW-apoB), an integrated metric designed to reflect the relative atherogenicity of apoB-containing lipoproteins. Among statin-treated patients with elevated triglycerides (TG) , RW-apoB was found to more effectively identify individuals at i
- SECAmarin Corporation plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - AMARIN CORP PLC\UK (0000897448) (Filer)
- SECSEC Form 10-Q filed by Amarin Corporation plc10-Q - AMARIN CORP PLC\UK (0000897448) (Filer)
- SECAmarin Corporation plc filed SEC Form 8-K: Results of Operations and Financial Condition8-K - AMARIN CORP PLC\UK (0000897448) (Filer)
- PRAmarin Reports 2026 First Quarter Financial ResultsTotal Revenue Increased Led by Higher International Sales Generated Positive Cash Flow and Reiterates Expectation for Full Year Positive Cash Flow Recently Updated Industry Guidelines Expand Global Medical Society Endorsements Supporting the Use of Icosapent Ethyl (IPE) in Contemporary Lipid and Cardiovascular Risk Management DUBLIN, Ireland and BRIDGEWATER, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the first quarter ended March 31, 2026 (Q1 2026). "Our results for Q1 2026 reflected the early yet measurable progress generated by
- INSIDERSEC Form 4 filed by Bonfiglio Patrice Eadon4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
- INSIDERSEC Form 4 filed by Cohen Paul4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
- INSIDERSEC Form 4 filed by Sullivan Diane E.4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
- INSIDERSEC Form 4 filed by Sterling Louis Iii4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
- INSIDERSEC Form 4 filed by Horn Keith4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
- INSIDERSEC Form 4 filed by Odysseas Kostas D4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
- INSIDERSEC Form 4 filed by O'Connor Oliver4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
- PRAmarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026DUBLIN and BRIDGEWATER, N.J., April 15, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report first quarter 2026 financial results and conduct a conference call on Wednesday, April 29, 2026. The Company will issue a press release detailing its first quarter 2026 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET. Information on how to participate is as follows. Access to the live call:Via telephone: Dial in within the United States: 888-506-0062 International dial in: 973-528-0011Access Code: 543818 Via online
- SECSEC Form DEF 14A filed by Amarin Corporation plcDEF 14A - AMARIN CORP PLC\UK (0000897448) (Filer)
- PRAmerican College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk ReductionDUBLIN and BRIDGEWATER, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) ("Amarin"), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today highlighted the important scientific and educational activities featured at the American College of Cardiology (ACC) Scientific Sessions 2026 that emphasized elevated and high triglycerides (TG) as a contributor to residual cardiovascular (CV) risk and the role that icosapent ethyl (IPE) plays in contemporary lipid and cardiovascular risk management. Scientific dialogue across the sessions consistently reinforced that substantial residual CV risk can persist in many patients beyond lo
- INSIDERSEC Form 4 filed by Fishman Peter L.4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
- SECSEC Form PRE 14A filed by Amarin Corporation plcPRE 14A - AMARIN CORP PLC\UK (0000897448) (Filer)
- SECAmarin Corporation plc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - AMARIN CORP PLC\UK (0000897448) (Filer)
- PRAmarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia GuidelineDUBLIN and BRIDGEWATER, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) ("Amarin"), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, applauded the recommendation that the treatment of CV risk in patients with hypertriglyceridemia be part of a broader dyslipidemia management as discussed in the 2026 American College of Cardiology (ACC) / American Heart Association (AHA)/Multisociety Dyslipidemia Guideline Update.i These newly-issued, evidenced-based recommendations summarize the clinical role of icosapent ethyl (IPE) in reducing cardiovascular (CV) risk in statin-treated patients with elevated triglycerides (TG) and full
- PRNew REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & ExpoDUBLIN and BRIDGEWATER, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today announced that additional REDUCE-IT patient subgroup analysis and additional mechanistic data on potential multifactorial biologic activities will be presented at the American College of Cardiology's Annual Scientific Session & Expo, March 28-30, 2026, in New Orleans, LA. Featured Amarin-supported abstracts to be presented by academic collaborators (italicized below) at ACC Scientific Sessions 2026 include: Oral Presentation Efficacy of Icosapent Ethyl Among Patients at Extreme Cardiovascular
- SECSEC Form 10-K filed by Amarin Corporation plc10-K - AMARIN CORP PLC\UK (0000897448) (Filer)
- PREffects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive CardiologyPeer-reviewed paper indicates icosapent ethyl (IPE) was associated with fewer total hospitalizations and fewer days lost due to hospitalization and death, providing additional insights on the effects of IPE on patient-centered measures of total disease burden DUBLIN and BRIDGEWATER, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today highlighted recently published data in the European Journal of Preventive Cardiology showing in a post hoc analysis of the landmark REDUCE-IT study that, among statin-treated participants with elevated triglycerides and known CVD or with di
- SECAmarin Corporation plc filed SEC Form 8-K: Results of Operations and Financial Condition8-K - AMARIN CORP PLC\UK (0000897448) (Filer)
- PRAmarin Reports Fourth Quarter and Full Year 2025 Financial ResultsStrategic Initiatives and Refined Business Model Produced Financial and Operating Efficiencies Established Long-Term License and Supply Agreement to Commercialize VAZKEPA® Across Europe and Sustained U.S. Market Leadership for VASCEPA® Franchise Total of 45 Publications (Abstracts, Posters, Manuscripts) Furthering the Expansion of the VASCEPA® /VAZKEPA® (icosapent ethyl) Body of Knowledge Supported in 2025 DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the fourth quarter and full year ended December 31, 20
- PRThis American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular DiseaseDUBLIN and BRIDGEWATER, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today issued a call to action for American Heart Month emphasizing a message that cannot wait: the United States has an opportunity to significantly reduce heart attacks, strokes, and cardiovascular deaths by prioritizing the use of proven, existing therapies that are widely available, yet significantly underutilized. Despite decades of scientific advances and clear guideline recommendations, millions of patients at high risk for CVD remain untreated or undertreated. The latest 2026 American Heart Asso
AMRN FAQ
6 questionsWhat does Amarin Corporation plc do?
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the...Where does AMRN stock trade?
Amarin Corporation plc (AMRN) is listed on NASDAQ.What sector and industry is AMRN in?
Amarin Corporation plc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about AMRN?
Amarin Corporation plc has had 8 recent analyst actions on file. The most recent action was from JP Morgan: Underweight on 2023-11-20.What companies are similar to AMRN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare AMRN side-by-side with any of them on Quantisnow.How can I track AMRN on Quantisnow?
Quantisnow aggregates Amarin Corporation plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AMRN to receive live email and push alerts on every new disclosure.